PC
Processa Pharmaceuticals, Inc.
PCSA · NASDAQ
$1.88 -1.57% (-$0.03)
1M -15.21%
Market Cap $5.09M
P/E Ratio -
Div. Yield -
ROE 394.24%
Bulios Fair Price
$2.17
15.4% upside
Current Price
$1.88
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PCSA is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
-
N/A P/E N/A
PEG N/A
EV/EBITDA N/A
Growth
0 /100
Declining Book val. growth 9.28%
EPS growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
40 /100
Average ROIC 4,051.82%
Asset turnover 0.00x
ROE 394.24%
Debt
12 /100
High Current ratio 0.87x
Int. coverage -6,708.03x
Debt/Equity N/A
Stability
74 /100
Stable Beta 0.97x
Profitable years 0
EPS volatility 17.57%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PCSA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
George K. Ng
Employees
12
Headquarters
Vero Beach
Upcoming events
29 OCT
Earnings
Upcoming earnings report